Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Enzon Pharmaceuticals Inc (ENZN) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
333 EAST BUTTERFIELD ROAD, SUITE 400 LOMBARD, IL 60148 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2026 MRQ | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 42,574 | 46,859 | 47,012 | 46,982 | 47,641 | 48,142 | |||
| Cash and cash equivalent | 42,574 | 46,859 | 47,012 | 46,982 | 47,641 | 48,142 | |||
| Receivables | |||||||||
| Inventory, net of allowances, customer advances and progress billings | |||||||||
| Inventory | |||||||||
| Other current assets | 239 | 293 | 331 | 405 | 85 | 59 | |||
| Other undisclosed current assets | 31 | ||||||||
| Total current assets: | 42,813 | 47,152 | 47,343 | 47,387 | 47,726 | 48,232 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | |||||||||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | |||||||||
| Intangible asset, including goodwill, after accumulated amortization | |||||||||
| Goodwill | |||||||||
| Intangible asset, excluding goodwill, after accumulated amortization | |||||||||
| Deferred income tax assets | 17 | 359 | 202 | ||||||
| Other noncurrent assets | |||||||||
| Other undisclosed noncurrent assets | |||||||||
| Total noncurrent assets: | 17 | 359 | 202 | ||||||
| Other undisclosed assets | 28 | ||||||||
| TOTAL ASSETS: | 42,813 | 47,169 | 47,702 | 47,589 | 47,754 | 48,232 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 731 | 403 | 439 | 424 | 403 | 412 | |||
| Accounts payable | 331 | 331 | 331 | 331 | 331 | 302 | |||
| Accrued liabilities | 400 | 72 | 108 | 93 | 72 | 110 | |||
| Debt | |||||||||
| Other undisclosed current liabilities | 1,275 | 1,275 | 1,275 | ||||||
| Total current liabilities: | 731 | 1,678 | 1,714 | 1,699 | 403 | 412 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | |||||||||
| Long-term debt, excluding current maturities | |||||||||
| Liabilities, other than long-term debt | |||||||||
| Operating lease, liability | |||||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | |||||||||
| Total liabilities: | 731 | 1,678 | 1,714 | 1,699 | 403 | 412 | |||
| Temporary equity, including noncontrolling interest | |||||||||
| Equity | |||||||||
| Equity, attributable to parent | (2,525) | 3,008 | 3,505 | 3,407 | 4,868 | 7,360 | |||
| Common stock | 742 | 742 | 742 | 742 | 742 | 742 | |||
| Additional paid in capital | 70,034 | 72,158 | 73,433 | 74,708 | 75,983 | 78,006 | |||
| Accumulated other comprehensive loss | |||||||||
| Accumulated deficit | (73,301) | (69,892) | (70,670) | (72,043) | (71,857) | (71,388) | |||
| Equity, attributable to noncontrolling interest | |||||||||
| Total equity: | (2,525) | 3,008 | 3,505 | 3,407 | 4,868 | 7,360 | |||
| Other undisclosed liabilities and equity | 44,607 | 42,483 | 42,483 | 42,483 | 42,483 | 40,460 | |||
| TOTAL LIABILITIES AND EQUITY: | 42,813 | 47,169 | 47,702 | 47,589 | 47,754 | 48,232 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2026 TTM | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,921 | 26 | 2,261 | 26 | 701 | 52 | ||
| Net investment income | 1,921 | 2,452 | 2,261 | |||||
| Cost of revenue (Other undisclosed Cost of revenue) | ||||||||
| Gross profit: | 1,921 | 26 | 2,261 | 26 | 701 | 52 | ||
| Operating expenses | (5,311) | (1,353) | (1,044) | (1,058) | (1,170) | (1,357) | ||
| Other undisclosed operating loss | (1,921) | (2,261) | ||||||
| Operating loss: | (5,311) | (1,327) | (1,044) | (1,032) | (469) | (1,305) | ||
| Nonoperating income (Other Nonoperating income) | 646 | 7 | 1 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (5,311) | (1,327) | (1,044) | (386) | (462) | (1,304) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 1,921 | 2,452 | 2,261 | |||||
| Income (loss) from continuing operations before income taxes: | (3,390) | 1,125 | 1,217 | (386) | (462) | (1,304) | ||
| Income tax expense (benefit) | (19) | (347) | 156 | 200 | (7) | (7) | ||
| Income (loss) from continuing operations: | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (469) | (1,311) | |
| Net income (loss): | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
| Other undisclosed net income attributable to parent | ||||||||
| Net income (loss) attributable to parent: | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
| Preferred stock dividends and other adjustments | (2,124) | (1,275) | (1,275) | (1,275) | (2,023) | (460) | ||
| Net income (loss) available to common stockholders, diluted: | (5,533) | (497) | 98 | (1,461) | (2,492) | (1,771) | ||
Comprehensive Income ($ in thousands)
| 3/31/2026 TTM | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
| Other comprehensive loss | ||||||||
| Comprehensive income (loss): | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | ||||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (3,409) | 778 | 1,373 | (186) | (469) | (1,311) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.
An easy way to get professional financial analysis in one click
Load financial statements → click "Get report" → Your report is ready.
No financial analysis knowledge required!